TARSTarsus Pharmaceuticals, Inc.
Is it safe?
Forensics clean, with a caveat: a safe balance sheet, but heavy debt (BB) and big price swings.
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$5.2M, 90 days to Oct 8, 2026), selling is often routine.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -78% · now 19% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can TARS take a bad year?
Tarsus Pharmaceuticals, Inc. holds $377M more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 7.74
Altman Z-score · safe zone, above 3
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
Details›
- Total debtQ2 2026
- $73M
- Cash and short-term investments
- $450M
- Net cash
- $377M
- EBITDA, trailing twelve months
- −$47M
- Operating profit, trailing twelve months
- −$49M
- Debt / equity
- 0.21×
- Annualised volatilitytwo years of daily moves
- 47%
- Worst drawdown on file
- −78%
- Below its 52-week high
- 19%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.